Gene therapy VGN-R13 for ALS safety and tolerability
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed ALS diagnosis, but it must not be caused by SOD1 or FUS gene mutations.
- Your first ALS symptoms started less than 2 years ago.
- Your lung function test (FVC) is at least 50% of normal for your age, gender, and height.
- You are not currently taking certain strong medications or have not used other ALS drugs or gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called SNUG01 for people with ALS (a disease that weakens muscles). The goal is to see if it's safe and might slow down the disease, especially for those diagnosed within the last 2 years.
This study tests an experimental gene therapy called XT-150, which is given as an injection into the fluid around the spinal cord. The goal is to see if it is safe and to gather information that could help treat ALS muscle weakness.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
This trial tests a new drug called RAG-21 in people with ALS who have a specific genetic change (FUS gene mutation). The goal is to see if it is safe and effective in slowing the disease.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.